Email
Print
Predictive Breast Cancer Gene Testing Market - Forecast(2024 - 2030)
Predictive Breast Cancer Gene Testing Market Overview
The Predictive Breast Cancer Gene Testing Market size is estimated to reach $2.4 billion by 2028, growing at a CAGR of 11.5% during the forecast period 2023-2028. The rising count of awareness programs by governments to decrease the morbidity rate of breast cancer is set to drive the Predictive Breast Cancer Gene Testing Market. The recognition of high penetrant genes with research based on candidate gene testing is set to propel the growth of the Predictive Breast Cancer Gene Testing Industry during the forecast period 2023-2028. According to World Health Organization, as of 2020, there were 7.8 million women alive who were diagnosed with breast cancer in the past 5 years, making it the world's most prevalent cancer. On the basis of gene type, the Predictive Breast Cancer Gene Testing Market is segmented into high penetrant genes, intermediate penetrant genes and low penetrant genes.
Predictive Breast Cancer Gene Testing Market Report Coverage
The “Predictive Breast Cancer Gene
Testing Market Report - Forecast (2023-2028)” by IndustryARC,
covers an in-depth analysis of the following segments in the Predictive Breast Cancer Gene
Testing Market.
Key Takeaways
- Geographically, North America (Predictive Breast Cancer Gene Testing market share) accounted for the highest revenue share in 2022 and it is poised to dominate the market over the period 2023-2028 due to rising awareness regarding breast cancer involving high penetrant genes in the North American region.
- The growth of the Predictive Breast Cancer Gene Testing Market is being driven by the rising application of predictive breast cancer gene testing in breast cancer hospitals and clinics. However, the soaring initial capital financing is one of the major factors hampering the growth of the Predictive Breast Cancer Gene Testing Market.
- The Predictive Breast Cancer Gene Testing Market Detailed Analysis of the Strengths, Weaknesses and Opportunities of the prominent players operating in the market would be provided in the Predictive Breast Cancer Gene Testing Market report.
Predictive Breast Cancer Gene Testing Market: Market Share (%) by Global Region, 2022
Predictive Breast Cancer Gene Testing Market Segment Analysis - by Gene Type
The Predictive Breast Cancer Gene Testing Market based on gene type can be further segmented into High Penetrant Genes, Intermediate Penetrant Genes and Low Penetrant Genes. The High Penetrant Genes Segment held the largest share of the Predictive Breast Cancer Gene Testing market in 2022. This growth is driven by high penetrant genes like BRCA1 and BRCA2 genes being the most typical cause of hereditary breast cancer. The pathogenic (injurious) variants in the breast cancer susceptibility genes 1 and 2 [BRCA1 and BRCA2 (BRCA1/2)] are further propelling the growth of the High Penetrant Genes segment. Furthermore, the High Penetrant Genes segment is estimated to grow at the fastest CAGR of 12.3% during the forecast period 2023-2028 due to rising observations of BRCA1 and BRCA2 germline mutations accounting for up to 30% of inheritable breast cancers.
Predictive Breast Cancer Gene Testing Market Segment Analysis - by End-user
The Predictive Breast Cancer Gene Testing Market based on end-user can be further segmented into Clinical Laboratories, Cancer Hospitals and Research Laboratories. The Cancer Hospitals Segment held the largest share of the Predictive Breast Cancer Gene Testing market in 2022. This growth is driven by the surging application of predictive breast cancer gene testing in cancer hospitals to decide the risk of a person developing breast cancer. The increasing number of private firms providing breast cancer gene tests to doctors in European cancer hospitals is further propelling the growth of this segment. Furthermore, the Clinical Laboratories segment is estimated to grow at the fastest CAGR of 13.5% during the forecast period 2023-2028. It would be due to the diagnosis of breast cancer being based on clinical evaluation, imaging and histopathological analysis of the tumor tissue which may be performed in clinical laboratories and clinics.
Predictive Breast Cancer Gene Testing Market Segment Analysis - by Geography
The Predictive Breast Cancer Gene Testing Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America dominated the Predictive Breast Cancer Gene Testing market with a 38% share of the overall market in 2022. The growth of this region is driven by the increasing predominance of breast cancer in the U.S. in the North American region. The surging R&D activities are further propelling the growth of the Predictive Breast Cancer Gene Testing Industry, thereby contributing to the Predictive Breast Cancer Gene Testing Industry Outlook, in the North American region. Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR over the forecast period 2023-2028. This growth is owing to factors like accelerated development in the Asia-Pacific region. The rising economies with advanced hospitals and clinics are further fueling the progress of the Predictive Breast Cancer Gene Testing Market in the Asia-Pacific region.
Predictive Breast Cancer Gene Testing Market Drivers
Vital Significance of Predictive Breast Cancer Gene Testing:
As per World Health Organization (WHO), as of the end of 2020, there were 7.8 million women alive who were diagnosed with breast cancer in the previous 5 years, making it the most prevalent cancer in the world. High penetrant genes pertaining to breast cancer susceptibility show a more than tenfold comparative risk of breast cancer. Predictive breast cancer gene testing is performed to recognize the risk of developing breast cancer in a person having a family history of this ailment. Earlier discovery of breast cancer assists in entirely healing the patient and rescuing the concerned breast. The vital significance of predictive breast cancer gene testing is therefore fueling the growth of the Predictive Breast Cancer Gene Testing Industry, thereby contributing to the Predictive Breast Cancer Gene Testing Industry Outlook during the forecast period 2023-2028.
Extensive Investigations Pertaining to Intermediate Penetrant Genes:
RAD50 may be an intermediate-penetrant breast cancer predisposition gene. However, conclusive outcomes to date pertain only to a founder mutation discovered in the Finnish population; similarly RAD51C, though its notable association seems to be with ovarian cancer (Meindl et al., 2010). The rarity of mutations and moderate connected risks are such that the attributable risk of mutations in these genes is low: together CHEK2, ATM, BRIP1 and PALB2 account for nearly 2.3% of excess familial risk. The extensive investigations pertaining to intermediate penetrant genes are therefore driving the growth of the Predictive Breast Cancer Gene Testing Market during the forecast period 2023-2028.
Predictive Breast Cancer Gene Testing Market Challenges
Search for Low Penetrant Genes Pertaining to Breast Cancer:
15% to 20% of the familial clustering of breast cancer is elucidated by the impacts of highly penetrant mutations in BRCA1 and BRCA2. A candidate gene technique is gradual and comparatively high-priced and has not until now produced unequivocal positive outcomes for any individual gene. The genetic architecture of breast cancer including the figure and typical features of predisposing genetic variants is still not established. These issues are thus hampering the growth of the Predictive Breast Cancer Gene Testing Market.
Key Market Players
Product launches, product approvals, patents and events, acquisitions, partnerships and collaborations are key strategies adopted by players in the Predictive Breast Cancer Gene Testing Market. The top 10 companies in the Predictive Breast Cancer Gene Testing market are:
- Myriad Genetics, Inc.
- Complete Genomics Inc.
- Ambry Genetics
- PreventionGenetics, LLC
- Illumina, Inc.
- F. Hoffmann-La Roche AG (Roche)
- Thermo Fisher Scientific Inc.
- PerkinElmer Genomics
- Quest Diagnostics
- Iverson Genetic Diagnostics Inc.
Recent Developments
- In November 2022, Myriad Genetics, Inc., declared the introduction of UroSuite. This is an all-inclusive suite of genetic risk assessment tests that cover every phase of prostate cancer care. UroSuite involves Myriad’s Prolaris® Prostate Cancer Test, MyRisk™ Hereditary Cancer Test, BRACAnalysis CDx® and Precise™ Tumor Molecular Profile Test.
- In November 2022, Myriad Genetics, Inc., declared that it has gained Gateway Genomics, LLC. It is the developer of SneakPeek® Early Gender DNA Test. SneakPeek discloses a baby’s gender at six weeks into pregnancy.
- In August 2021, Myriad Genetics, Inc. introduced a novel version of its market-leading MyRisk Hereditary Cancer Test. For the first time, women of all ancestries can now acquire a personalized polygenic breast cancer risk assessment. This is in conjunction with the market’s most precise hereditary cancer test.
Relevant Reports:
Report Code: HCR 0195
Report Code: HCR 0965
Report Code: HCR 0055
For more Lifesciences and Healthcare Market reports, please click here